Actively Recruiting
Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)
Led by University of California, Irvine · Updated on 2026-03-10
20
Participants Needed
1
Research Sites
100 weeks
Total Duration
On this page
Sponsors
U
University of California, Irvine
Lead Sponsor
B
BillionToOne Inc.
Collaborating Sponsor
AI-Summary
What this Trial Is About
This is a phase 1b prospective, single arm, open-label trial determining the efficacy and feasibility of using a response-guided approach to help guide neoadjuvant chemotherapy in subjects with Stage IB, II or Stage III adenocarcinoma of the stomach or gastroesophageal junction (GEA).
CONDITIONS
Official Title
Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients must have histologically or cytologically confirmed adenocarcinoma of the stomach or gastroesophageal junction (GEA) or other GE histologies treated per NCCN guidelines
- Stage IB, II, or III GEA eligible for (neo)adjuvant doublet or triplet chemotherapy for up to 6 months
- Age 18 years or older
- ECOG performance status 0, 1, or 2
- Life expectancy greater than 6 months
- Adequate organ and marrow function including hemoglobin ≥7 g/dL, absolute neutrophil count ≥1,500/mcL, platelets ≥80,000/mcL, normal total bilirubin, AST/ALT ≤5 times upper limit of normal, creatinine less than 2 times upper limit of normal
- Women of child-bearing potential and men must agree to use contraception during study and for 90 days after
- Ability to understand and willingness to sign informed consent
- All races, ethnic groups, and genders eligible including non-English speakers, deaf, hard of hearing, and illiterate individuals
You will not qualify if you...
- Receiving other investigational agents
- Known distant metastases from gastroesophageal adenocarcinoma
- History of allergic reactions to study agents
- Uncontrolled illnesses such as active infection, symptomatic heart failure, unstable angina, arrhythmia, or psychiatric/social conditions limiting compliance
- History of another primary cancer requiring active treatment or expected treatment within 12 months
- Inability to comply with study and follow-up procedures
- Pregnant or nursing women
- Prior organ, bone marrow, or non-autologous stem cell transplants
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Chao Family Comprehensive Cancer Center, University
Orange, California, United States, 92868
Actively Recruiting
Research Team
C
Chao Family Comprehensive Cancer Center University of California, Irvine
CONTACT
U
University of California Irvine Medical
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here